Form 4: Cullinan Therapeutics CMO Sells Shares for Tax

Cullinan Therapeutics' Chief Medical Officer, Jeffrey Alan Jones, sold 4,982 shares of common stock at $13.62 per share on February 20, 2026, to cover personal income tax obligations.

Summary

• Jeffrey Alan Jones, Chief Medical Officer of Cullinan Therapeutics, Inc. (CGEM), reported a sale of common stock.
• The transaction occurred on February 20, 2026.
• A total of 4,982 shares were sold at a price of $13.62 per share.
• The sale was executed to cover personal income tax obligations arising from the vesting of restricted stock units.
• Following this transaction, Jones beneficially owns 164,550 shares of common stock directly.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation. The sale is non-discretionary, solely for tax purposes following RSU vesting, and does not reflect a change in management's confidence in the company.

Positives

• The underlying event, vesting of restricted stock units, indicates compensation for the executive.
• The sale was non-discretionary, specifically to cover tax obligations, which is a common and expected event for executives receiving equity compensation.

Future Outlook

NA

Management Comments

• Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax obligations upon the vesting of restricted stock units are a common and routine occurrence in the biotechnology and pharmaceutical industries, reflecting standard equity compensation practices rather than a discretionary move to reduce exposure to the company's stock.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary sale for tax purposes.
• No direct impact on employees, customers, suppliers, or creditors from this specific transaction.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by a Chief Medical Officer to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and do not typically signal a change in the company's fundamental outlook or management's confidence. Therefore, a 'hold' recommendation is appropriate as this event does not provide new information warranting a change in investment thesis.

Keywords

Cullinan Therapeutics, CGEM, Jeffrey Alan Jones, Chief Medical Officer, Insider Sale, Form 4, Restricted Stock Units, Tax Obligations, Equity Compensation, Rule 10b5-1